A comparison of damage accrual across different calendar periods in systemic lupus erythematosus patients

Lupus

Volumn 15, Issue 9, 2006, Pages 590-594

  Pineau, Christian A ^a,c   Bernatsky, S ^a   Abrahamowicz, M ^a,b   Neville, C ^a   Karp, I ^a,b   Clarke, A E ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Damage; Systemic lupus erythematosus (SLE); Systemic Lupus International Collaborating Clinics American College of Rheumatology Damage Index (SLICC ACR DI)

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; CANADA; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ODDS RATIO; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33750526654     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306071874     Document Type: Article

References (24)

1. Nossent H, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969-978.
2. Takada K, Illei G, Boumpas D. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-162.
3. Austin H, Klippel J, Balow J et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
4. Mosca M, Ruiz-Irastorza G, Khamashta M, Hughes G. Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001; 1: 1065-1076.
5. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001; 10: 152-153.
6. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. American Journal of Kidney Diseases 2004; 43: 197-208.
7. Lieberman JD, Schatten S. Treatment-disease-modifying therapies. Rheumatic Disease Clinics of North America 1988; 14: 223-243.
8. Wallace DJ, Hanh BH, Dubois EL. Dubois' lupus erythematosus, sixth edition. Lippincott Williams & Wilkins, 2002.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1998; 41: 751.
10. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
11. Gladman DD, Ginzler EM, Goldsmith CH et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. [Congresses]. Journal of Rheumatology 1992; 19: 1820-1821.
12. Gladman D, Urowitz M, Goldsmith C et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-813.
13. Bootsma H, Derksen R, Jaegers S et al. Usefulness of the SLICC/ACR Damage Index in patients with systemic lupus erythematosus. Arthritis and Rheumatism 1997; 40 (Suppl 9): S160 [abstract].
14. Thumboo J, Lee HY, Pong KY et al. Accuracy of medical record scoring of the SLICC/ACR Damage Index for systemic lupus erythematosus. Lupus 2000; 9: 358-362.
15. Bernatsky S, Pineau C, Abrahamowicz M, Neville C, Karp I, Clarke A. A comparison of retrospective and prospective evaluations of the SLICC/ACR Damage Index scores for systemic lupus erythematosus. Journal of Rheumatology 2005 (Accepted).
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang C. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
17. ArceSalinas A, Cardiel MH, Guzman J, AlcocerVarela J. Validity of retrospective disease activity assessment in systemic lupus erythematosus. Journal of Rheumatology 1996; 23: 846-849.
18. Wluka AE, Liang MH, Partridge AJ et al. Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. Arthritis and Rheumatism 1997; 40: 57-61.
19. Newcombe R. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-890.
20. Wilson E. Probable inference, the law of succession, and statistical inference. Journal of the American Statistical Association 1927; 22: 209-212.
21. Hawker GA, Gabriel SE, Bombardier C, Goldsmith CH, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993; 20: 657-660.
22. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 93-96.
23. Klippel JH. Systemic lupus erythematosus: demographics, prognosis, and outcome. Journal of Rheumatology 1997; 24: 67-71.
24. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. Journal of Rheumatology 2000; 27: 685-691.